• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Incidence of Brain Metastases and Preliminary Evidence of Intracranial Activity With Sotorasib in Patients With -Mutant Non-Small-Cell Lung Cancer.

作者信息

Lamberti Giuseppe, Aizer Ayal, Ricciuti Biagio, Alessi Joao V, Pecci Federica, Tseng Shu-Chi, Sholl Lynette M, Nishino Mizuki, Awad Mark M

机构信息

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA.

Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, MA.

出版信息

JCO Precis Oncol. 2023 Feb;7:e2200621. doi: 10.1200/PO.22.00621.

DOI:10.1200/PO.22.00621
PMID:36809054
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10309542/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebde/10309542/8ef84ec29dfa/po-7-e2200621-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebde/10309542/e09513137e45/po-7-e2200621-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebde/10309542/bff2147ce2a4/po-7-e2200621-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebde/10309542/d10969f771c4/po-7-e2200621-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebde/10309542/e86dc711d790/po-7-e2200621-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebde/10309542/df6edeceb32d/po-7-e2200621-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebde/10309542/ab1a0fb39d74/po-7-e2200621-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebde/10309542/8ef84ec29dfa/po-7-e2200621-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebde/10309542/e09513137e45/po-7-e2200621-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebde/10309542/bff2147ce2a4/po-7-e2200621-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebde/10309542/d10969f771c4/po-7-e2200621-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebde/10309542/e86dc711d790/po-7-e2200621-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebde/10309542/df6edeceb32d/po-7-e2200621-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebde/10309542/ab1a0fb39d74/po-7-e2200621-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ebde/10309542/8ef84ec29dfa/po-7-e2200621-g008.jpg

相似文献

1
Incidence of Brain Metastases and Preliminary Evidence of Intracranial Activity With Sotorasib in Patients With -Mutant Non-Small-Cell Lung Cancer.KRAS突变型非小细胞肺癌患者脑转移的发生率及索托拉西布颅内活性的初步证据
JCO Precis Oncol. 2023 Feb;7:e2200621. doi: 10.1200/PO.22.00621.
2
KRAS Inhibitor Resistance in -Amplified Non-Small Cell Lung Cancer Induced By RAS- and Non-RAS-Mediated Cell Signaling Mechanisms.KRAS 抑制剂耐药性在 -扩增非小细胞肺癌中由 RAS 和非 RAS 介导的细胞信号转导机制诱导。
Clin Cancer Res. 2021 Oct 15;27(20):5697-5707. doi: 10.1158/1078-0432.CCR-21-0856. Epub 2021 Aug 7.
3
Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.索托拉西布：一种用于治疗KRAS G12C突变的非小细胞肺癌的药物。
Drugs Today (Barc). 2022 Apr;58(4):175-185. doi: 10.1358/dot.2022.58.4.3400573.
4
DNA replication stress and mitotic catastrophe mediate sotorasib addiction in KRAS-mutant cancer.DNA 复制应激和有丝分裂灾难介导 KRAS 突变型癌症对索托拉西布的成瘾性。
J Biomed Sci. 2023 Jun 29;30(1):50. doi: 10.1186/s12929-023-00940-4.
5
BCL-X PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRAS-mutated cancers.BCL-X PROTAC降解剂DT2216在KRAS突变癌症的临床前模型中与索托拉西布协同作用。
J Hematol Oncol. 2022 Mar 9;15(1):23. doi: 10.1186/s13045-022-01241-3.
6
Sotorasib: First Approved Mutation Inhibitor for the Treatment of Non-small Cell Lung Cancer.索托拉西布：首个获批用于治疗非小细胞肺癌的突变抑制剂。
Curr Med Chem. 2023;30(9):1000-1002. doi: 10.2174/0929867329666220907161505.
7
The promise and peril of KRAS G12C inhibitors.KRAS G12C 抑制剂的前景与挑战。
Cancer Cell. 2021 Aug 9;39(8):1059-1061. doi: 10.1016/j.ccell.2021.07.011.
8
KRAS G12C-Mutant Non-Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular Testing.KRAS G12C 突变型非小细胞肺癌：生物学、研发治疗策略和分子检测。
J Mol Diagn. 2021 May;23(5):507-520. doi: 10.1016/j.jmoldx.2021.02.002. Epub 2021 Feb 20.
9
KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.KRAS 继发突变导致对 KRAS G12C 抑制剂（索托拉西布和阿达格拉西布）获得性耐药及克服策略：体外实验的见解。
J Thorac Oncol. 2021 Aug;16(8):1321-1332. doi: 10.1016/j.jtho.2021.04.015. Epub 2021 May 7.
10
Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC).社论：索托拉西布获批成为首个针对 KRAS G12C 突变型晚期非小细胞肺癌（NSCLC）的靶向治疗药物。
Med Sci Monit. 2022 Nov 1;28:e938746. doi: 10.12659/MSM.938746.

引用本文的文献

1
Resistance mutations and the blood-brain barrier: Key challenges in targeted treatment of brain metastatic non-small cell lung cancer.耐药突变与血脑屏障：脑转移非小细胞肺癌靶向治疗中的关键挑战
Acta Pharm Sin B. 2025 Aug;15(8):3833-3851. doi: 10.1016/j.apsb.2025.06.002. Epub 2025 Jun 7.
2
KRAS mutation subtypes in metastatic non-small cell lung cancer.转移性非小细胞肺癌中的KRAS突变亚型
Am J Cancer Res. 2025 Jul 15;15(7):3188-3196. doi: 10.62347/GYHT4724. eCollection 2025.
3
A genome-wide in vivo CRISPR activation screen identifies BACE1 as a therapeutic vulnerability of lung cancer brain metastasis.

本文引用的文献

1
Sotorasib Shows Intracranial Activity in Patients with Mutated Adenocarcinoma of the Lung and Untreated Active Brain Metastases.索托拉西布在伴有突变型肺腺癌和未经治疗的活动性脑转移的患者中显示出颅内活性。
Case Rep Oncol. 2022 Aug 26;15(2):720-725. doi: 10.1159/000525341. eCollection 2022 May-Aug.
2
Adagrasib in Non-Small-Cell Lung Cancer Harboring a Mutation.在携带有突变的非小细胞肺癌中使用阿达格拉西布。
N Engl J Med. 2022 Jul 14;387(2):120-131. doi: 10.1056/NEJMoa2204619. Epub 2022 Jun 3.
3
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With -Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study.
一项全基因组体内CRISPR激活筛选将β-分泌酶1鉴定为肺癌脑转移的一个治疗靶点。
Sci Transl Med. 2025 Jul 2;17(805):eadu2459. doi: 10.1126/scitranslmed.adu2459.
4
Matching-Adjusted Indirect Comparison of Sotorasib Versus Adagrasib in Previously Treated Advanced/Metastatic Non-Small Cell Lung Cancer Harboring KRAS G12C Mutation.在既往接受过治疗的携带KRAS G12C突变的晚期/转移性非小细胞肺癌中，索托拉西布与阿达格拉西布的匹配调整间接比较
Adv Ther. 2025 Jun 21. doi: 10.1007/s12325-025-03259-8.
5
Combination therapy of adagrasib and abemaciclib in non-small cell lung cancer brain metastasis models genomically characterized by KRAS-G12C and homozygous loss of CDKN2A.在以KRAS-G12C和CDKN2A纯合缺失为特征的非小细胞肺癌脑转移模型中，阿达格拉西布与阿贝西利的联合治疗。
Acta Neuropathol Commun. 2025 May 2;13(1):88. doi: 10.1186/s40478-025-01993-2.
6
Advances in the treatment of KRAS mutant non-small cell lung cancer.KRAS 突变型非小细胞肺癌的治疗进展
Cancer. 2025 Mar 15;131 Suppl 1(Suppl 1):e35783. doi: 10.1002/cncr.35783.
7
KRAS Inhibitors in Non-Small Cell Lung Cancer: A Review.非小细胞肺癌中的KRAS抑制剂：综述
Onco Targets Ther. 2024 Aug 24;17:683-695. doi: 10.2147/OTT.S473368. eCollection 2024.
8
Unique genomic alterations in the circulating tumor DNA of patients with solid tumors brain metastases.实体瘤脑转移患者循环肿瘤DNA中的独特基因组改变。
Neurooncol Adv. 2024 Apr 17;6(1):vdae052. doi: 10.1093/noajnl/vdae052. eCollection 2024 Jan-Dec.
9
Current pharmacologic treatment of brain metastasis in non-small cell lung cancer.非小细胞肺癌脑转移的当前药物治疗。
Clin Exp Metastasis. 2024 Oct;41(5):549-565. doi: 10.1007/s10585-024-10276-4. Epub 2024 Mar 11.
10
Safety and Intracranial Activity of Adagrasib in Patients With -Mutated Non-Small-Cell Lung Cancer and Untreated CNS Metastases in the KRYSTAL-1 Trial: A Case Series.KRYSTAL-1试验中阿达格拉西布治疗KRAS G12C突变的非小细胞肺癌及未经治疗的中枢神经系统转移患者的安全性和颅内活性：病例系列
JCO Precis Oncol. 2024 Feb;8:e2300447. doi: 10.1200/PO.23.00447.
CROWN 研究的事后分析：劳拉替尼治疗阳性晚期非小细胞肺癌患者的颅内疗效和安全性。
J Clin Oncol. 2022 Nov 1;40(31):3593-3602. doi: 10.1200/JCO.21.02278. Epub 2022 May 23.
4
Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer.阿达格拉西布（MRTX849）在脑转移中的活性：KRASG12C 突变型非小细胞肺癌患者的临床前模型和临床数据。
Clin Cancer Res. 2022 Aug 2;28(15):3318-3328. doi: 10.1158/1078-0432.CCR-22-0383.
5
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.25000 例患者前瞻性临床测序的转移模式的基因组特征分析。
Cell. 2022 Feb 3;185(3):563-575.e11. doi: 10.1016/j.cell.2022.01.003.
6
Mutational profiles of primary pulmonary adenocarcinoma and paired brain metastases disclose the importance of KRAS mutations.原发性肺腺癌和配对脑转移瘤的突变特征揭示了 KRAS 突变的重要性。
Eur J Cancer. 2021 Dec;159:227-236. doi: 10.1016/j.ejca.2021.10.006. Epub 2021 Nov 13.
7
Sotorasib for Lung Cancers with p.G12C Mutation.索托拉西布治疗 p.G12C 突变型肺癌。
N Engl J Med. 2021 Jun 24;384(25):2371-2381. doi: 10.1056/NEJMoa2103695. Epub 2021 Jun 4.
8
Efficacy of Alectinib in Patients with ALK-Positive NSCLC and Symptomatic or Large CNS Metastases.艾乐替尼治疗 ALK 阳性 NSCLC 伴症状性或大中枢神经系统转移患者的疗效。
J Thorac Oncol. 2019 Apr;14(4):683-690. doi: 10.1016/j.jtho.2018.12.002. Epub 2018 Dec 7.
9
CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).奥希替尼治疗 T790M 阳性晚期非小细胞肺癌患者的中枢神经系统疗效：一项随机 III 期试验（AURA3）的数据。
J Clin Oncol. 2018 Sep 10;36(26):2702-2709. doi: 10.1200/JCO.2018.77.9363. Epub 2018 Jul 30.
10
Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer.OncoPanel验证：一种用于检测癌症体细胞变异的靶向新一代测序分析方法
Arch Pathol Lab Med. 2017 Jun;141(6):751-758. doi: 10.5858/arpa.2016-0527-OA. Epub 2017 Mar 3.